Please login to the form below

Not currently logged in
Email:
Password:

tumours

This page shows the latest tumours news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer. Genetically engineered virus produces immune response in tumours. ... We look forward to working with Vyriad to explore this novel combination for patients with solid tumours.”.

Latest news

More from news
Approximately 8 fully matching, plus 961 partially matching documents found.

Latest Intelligence

  • Cancer in The Information Age: are we illuminated or inundated? Cancer in The Information Age: are we illuminated or inundated?

    It can make it easier to forget we’re treating people, not just tumours. ... As oncology moves away from an anatomical approach to tumour classification towards a more genomic model, cancers become more individualised.

  • Accelerating innovation Accelerating innovation

    leadership in neuroendocrine tumours - any therapeutic solutions [there] would be very interesting to us.”. ... sales muscle to go head-to-head with the very biggest players in tumour types like breast or lung.

  • Gene therapy Gene therapy

    Would there be off-target effects? Or challenges of tumour heterogeneity? And how easily would resistance to such an overtly targeted therapy arise?

  • Deal Watch March 2017 Deal Watch March 2017

    650. CytomX Therapeutics. BMS. Strategic collaboration. Probody platform to enhance tumour-targeting of antibodies. ... BioLineRx. Acquisition. Portfolio, including AGI-134, synthetic alpha-GaI immunotherapy for solid tumours.

  • Deal Watch February 2017 Deal Watch February 2017

    With a potential headline value of just over $2bn and $250m upfront, this deal brings Seattle Genetics, an ADC specialist itself, a product candidate that covers multiple solid tumour indications, including ... Acquisition - company. 2, 475. Immunomedics/

More from intelligence
Approximately 0 fully matching, plus 59 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics